Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Fig. 3

a Recurrence-free survival (RFS) by tumor subtype. b RFS by neoadjuvant chemotherapy (NACT) treatment regimen within hormone receptor (HR)-positive, HER2-nonamplified patients. c RFS by NACT treatment regimen within HER2-positive patients. d RFS by NACT treatment regimen within triple-negative patients with breast cancer. Some groups were too small to analyze, and survival could not be calculated (b, c, d). Additionally, the log-rank test could not be performed for HR-positive disease (b), owing to small sample size

Back to article page
\